Background: Given recent discrepant results from randomized controlled trials (RCTs), we
examined the totality of RCT evidence assessing the association between dipeptidyl …

Background Recent studies have suggested that dipeptidyl peptidase-4 inhibitors (DPP-4
inhibitors) may be associated with increased risk of heart failure (HF), but evidence was …

Background Previous meta-analyses evaluating the effectiveness of individual dipeptidyl
peptidase-4 (DPP-4) inhibitors on the risk of heart failure (HF) were limited because of the …

Background & aims Recently, the SAVOR TIMI-53 (Saxagliptin Assessment of Vascular
Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction …

Aims The association between glucose lowering in diabetes mellitus and major
cardiovascular (CV) outcomes is weak; indeed, some oral hypoglycemic agents are …

Opinion statement The increased risk of heart failure hospitalizations related to treatment
with the DPP-4 inhibitor saxagliptin observed in the SAVOR TIMI 53 trial, is likely not to be a …

Purpose Although recent reports suggest an association between saxagliptin and an
increased risk of admissions for heart failure, it is not clear whether dipeptidyl peptidase IV …

Heart failure is a major co-morbid association of diabetes mellitus. The incidence of heart
failure in diabetic vs. control subjects is 2-to 3-fold greater in every decade of life. 1 Similar …

Background Although recent clinical trials raised concerns about the risk for heart failure
(HF) in dipeptidyl peptidase-4 (DPP-4) inhibitor use, data on the cardiovascular risks in the …

The cardiovascular safety of DPP4 inhibitors as a class, especially in regards to heart failure,
has been questioned after the publication of first trials (SAVOR-TIMI 53 and EXAMINE) …